Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management

American Journal of Hematology

Volumn 90, Issue 8, 2015, Pages 739-745

  Vose, Julie M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUITINIB; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CHROMOSOME TRANSLOCATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FOLLICULAR LYMPHOMA; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERMEDIATE RISK POPULATION; LEUKOCYTE COUNT; LOW RISK POPULATION; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA CELL; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MARGINAL ZONE LYMPHOMA; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; AUTOTRANSPLANTATION; DISEASE MANAGEMENT; DRUG EFFECTS; GENE TRANSLOCATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; RISK ASSESSMENT; SPLEEN; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYCLIN D1; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; RISK ASSESSMENT; SPLEEN; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84937441039     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24094     Document Type: Article

References (64)

1. Gerard-Marchant R, Hamlin, I, Lennert K, et al. Classification of non-Hodgkin's lymphomas [letter]. Lancet 1974;2:405-408.
2. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Haematol 1974;3:39-45.
3. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma. A follicular variant of intermediate lymphocytic lymphoma. Cancer 1982;49:1429-34.
4. Harris NL, Jaffe, ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
5. Swerdlow SH, Campo, E, Harris N, et al. WHO Classification of Tumors of the Haematopietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
6. Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group. Blood 1997; 89:3909-3918.
7. Tiemann M, Schrader, C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29-38.
8. Ferrer A, Salaverria, I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007;109:2473-2480.
9. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469-1476.
10. Samaha H, Dumontet, C, Ketterer N, et al. Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 1998;34:329-336.
11. Romaguera JE, Medeiros, LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586-591.
12. Bertoni R, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007;39:1747-1753.
13. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006;24:22-27.
14. Rosenwald A, Wright, G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
15. Fernandez V, Salamero, O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-1418.
16. Bernard M, Gressin, R, Lefrere F, et al. Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. Leukemia 2001;15:1785-1791.
17. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62.
18. Jares P, Colomer, D, Campo E, et al. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012;122:3416-3423.
19. Gill S, Wolf, M, Prince HM, et al. [18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymph Myeloma 2008;8:159-165.
20. Ferrer A, Bosch, F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008;19:135-141.
21. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
22. Hoster E, Dreyling, M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 2008;111:558-565.
23. Geisler CH, Kolstad, A, Laurell A, et al. The mantle cell lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115:1530-1533.
24. Hartmann E, Fernandez, V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Onc 2008;26:4966-4972.
25. Martin P, Chadburn, A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Onc 2009;27:1209-1213.
26. Weisenburger DD, Vose, JM, Greiner TC, et al. Mantle cell lymphoma: A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190-196.
27. Foran JM, Rohatiner, AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Onc 2000;18:317-324.
28. Howard OM, Gribben, JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294.
29. Lenz G, Dreyling, M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992.
30. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. Nejm 2015;372:944-953.
31. Cohen BJ, Moskowitz, C, Straus D, et al. Cyclophsphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001;42:1015-1022.
32. Kluin-Nelemans JC, Hoster, E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma. Nejm 2012;376:520-531.
33. Rummel M, Niederle, N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, muticentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210.
34. Flinn IW, Van der Jagt RH, Kahl BS, et al. An open-level, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. Blood 2014;123:2944-2952.
35. Vidal L, Gafter-Gvili A, Dreyling M, et al. Rituximab maintenance (MR) for patients with mantel cell lymphoma (MCL)-A systemic review and meta-analysis of the randomized controlled trials (RCTs). Blood 2014; abstract 4466.
36. Dreyling M, Lenz, G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684.
37. Romaguera JE, Fayad, L, Rodriguez MA, et al. High rate of durable remission after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus HyperCVAD Alternating with Rituximab plus high-dose methotrexate and cytarabine. J Clin Onc 2005;23:7013-7023.
38. Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of HyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma: SWOG 0213. Ann Oncol 2013;24:1587-1593.
39. Vose J, Loberiza, F, Bierman P, et al. Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/high dose methotrexate and cytarabine (MC)±rituximab improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006;24:424a.
40. Budde LE, Guthrie, KA, Till GB, et al. Mantel cell lymphoma International Prognostic Index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem cell transplantation. J Clin Oncol 2011;29:3023-3029.
41. Giesler CH, Kolstad, A, Lurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A non-randomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
42. Kahl BS, Longo, WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423.
43. Delarue R, Haioun, C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013;121:48-53.
44. LeCase AS, Vandergrift, JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis form the NCCN NHL Database. Blood 2012;119:2093-2099.
45. Rummel M, Atta J, Welslau M. Bendamustine and rituximab (BR) are effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Onc 2005;23:3383-3389.
46. Visco C, Finotto, S, Pomponi F, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle cell non-Hodgkin lymphoma ineliglible for intensive regimens or autologous transplantation. J Clin Oncol 2013;31:1442-1449.
47. O'Connor OA, Wright, J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
48. Fisher RI, Bernstein SH Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
49. Goy A, Bernstein, SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
50. Friedberg JW, Vose, JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell lymphoma. Blood 2011;117:2807-2812.
51. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38.
52. Ansell SM, Inwards, DJ, Rowland KM, et al. low-dose single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113:508-514.
53. Hess G, Herbrecht, R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
54. Witzig TE, Reeder, CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everoliumus in relapsed aggressive lymphoma. Leukemia 2011;25:341-347.
55. Zinzani PL, Witzig TE, Vose J, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: Results of an international study (NHL-003). Blood 2008;112:262-267.
56. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mangle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) Study. J Clin Oncol 2013;49:2835.
57. Wang M, Fayad, L, Wagner-Bartak N, et al. Lenalidamide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012;13:716-723.
58. Wang L, Rule, S, Martin P, et al. Targeting BTK with Ibruitinib in relapsed or refractory mantle cell lymphoma. Nejm 2014;369:507-516.
59. Kahl B, Spurgeon, S, Furman RI, et al. Significant clinical activity of CAL-101, an isoform selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma. Blood 2014;123:3398-3405.
60. Wang M, Oki Y, Pro B, et al. Phase II study of Yttrium-90 Ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:5213-5218.
61. Smith MR, Linjun, A, Gordon LI, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by 90Y-Ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012;30:3119-3126.
62. Fenske TS, Carreras, J, Zhang M, et al. Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. J Clin Oncol 2013;49:2454-60.
63. Tam CS, Bassett, R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-4152.
64. Maris MB, Sandmaier, M, Storer FE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542.